Table of Contents
NEW YORK — Bristol-Myers Squibb Co. has made changes in its senior management team as part of a plan to evolve its business model, in which it’s creating a global, integrated commercial organization and expanding the scope of its finance organization.
BMS said Wednesday that Giovanni Caforio has been appointed executive vice president and chief commercial officer, a newly created position in which he will lead all of the pharmaceutical company’s commercial units across all geographies. Most recently president of BMS’ U.S. unit, he will be responsible for the global commercial strategy of the company and for the performance of commercial operations worldwide.
Charles Bancroft, executive vice president and chief financial officer, will assume an expanded role that includes the business development and strategy groups. Bancroft will be responsible for developing an integrated approach to finance, business development and strategy aimed at enhancing the company’s effectiveness in meeting its long-term goals.
Caforio and Bancroft will continue to report to chief executive officer Lamberto Andreotti and remain members of his senior management team.
In addition, BMS has appointed Murdo Gordon, senior vice president for U.S. oncology, as president, U.S. He will report to Caforio.
BMS added that Beatrice Cazala, executive vice president of commercial operations in charge of global commercialization for Europe and China, is in the process of transitioning to a new role in the company.
"By evolving our organization and expanding the roles of Giovanni and Charlie, I feel even more confident in the strength of my management team and our ability to take advantage of the most critical opportunities to build long-term sustainable growth," Andreotti said in a statement.
